As a proof of concept, we targeted programmed death-ligand 1 (PD-L1), which is expressed in 35–62% of gliomas [17,18], not for immune checkpoint inhibition but as a tumor-selective entry route for VEGF-siRNA delivery. The gene discussed is VEGFA; the disease is glioma.